Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lauflumide - NLS Pharmaceutics Ltd

Drug Profile

Lauflumide - NLS Pharmaceutics Ltd

Alternative Names: NLS-14; NLS-4

Latest Information Update: 26 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NeuroLifeSciences
  • Developer NLS Pharmaceutics Ltd; University of Lausanne
  • Class Behavioural disorder therapies; Benzhydryl compounds; Sleep disorder therapies; Small molecules
  • Mechanism of Action Alpha 1 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Hypersomnia; Narcolepsy
  • Discontinued Alzheimer's disease; Attention-deficit hyperactivity disorder

Most Recent Events

  • 26 Dec 2019 Chemical structure information added
  • 18 Dec 2019 Lauflumide - NLS Pharmaceutics is available for licensing as of 18 Dec 2019. https://nlspharma.com/
  • 18 Dec 2019 Discontinued - Phase-I for Alzheimer's disease in France before December 2019 (NLS Pharmaceutics pipeline, December 2019)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top